Iodine 131 tositumomab

N/A

Report date: 2025/09/04 17:54:13

Base Information

Drug NameIodine 131 tositumomab
Drug Alias Name托司妥莫单抗/I131-托司妥莫单抗Tositumomab/iodine (I131) tositumomab131-I-tositumomab托西莫单抗/I131-托西莫单抗碘[131I]托西莫单抗 +[11] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody murineBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody diagnosticsRadiation-emitting products > Radioactive therapeutic agent +[5] 
Mechanisms of ActionAnti-CD20
TargetsB-lymphocyte antigen CD20
Therapy Area/IndicationsMultiple MyelomaLymphoma, Mantle-CellLymphoma, Follicular +[9] 
Global Approved IndicationsLymphoma, Non-Hodgkin
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2003/06/27
Country/TerritoryCanadaUnited StatesUnited Kingdom +[4] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesCorixa Corp
China Registration ClassN/A

Develop Information

Active CompaniesGlaxosmithkline PlcNational Cancer InstituteUniversity Of Michigan Rogel Cancer Center
Inactive CompaniesCoulter Pharmaceutical IncStanford UniversityCorixa Corp +[7] 
Active IndicationsMultiple MyelomaLymphoma
Inactive IndicationsLymphoma, Mantle-CellLymphoma, FollicularLymphoma, B-Cell +[7] 

Other Information

ATC CodeV10XA53
Related LinksWikipediaDrugBankKEGG